Efficacy of a pure Ikr blockade with nifekalant in refractory neonatal congenital junctional ectopic tachycardia and careful attention to damaging the atrioventricular conduction during the radiofrequency catheter ablation in infancy

Hisaaki Aoki, MD, PhD,* Tsugutoshi Suzuki, MD, PhD,† Hikoro Matsui, MD, PhD,‡ Satoshi Yasukochi, MD,§ Hirofumi Saiki, MD, PhD,§ Hideaki Senzaki, MD, PhD,§ Yoshihide Nakamura, MD*

From the *Department of Pediatrics, Faculty of Medicine, Kinki University, Osaka, Japan, †Department of Pediatric Electrophysiology, Osaka City General Hospital, Osaka, Japan, ‡Division of Pediatric Cardiology, Nagano Children’s Hospital, Nagano, Japan, and §Department of Pediatric Cardiology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Introduction
Congenital junctional ectopic tachycardia (JET) is a rare idiopathic disorder that presents during infancy. It is caused by abnormal automaticity near the atrioventricular (AV) node or proximal His bundle. Although the survival rate has improved because of progress in medical treatment and catheter ablation (CA), JET is still associated with a high morbidity and mortality. There are some reports about the efficacy of medications such as amiodarone (AMD) and CA, but no reliable treatment has been established thus far. We experienced 2 cases of congenital JET, which were refractory to various antiarrhythmic agents, including AMD, but were well controlled with a nifekalant (NIF) infusion and successively underwent CA. The effectiveness of NIF for postoperative JET has been previously reported. However, to the best of our knowledge, this is the first report on the effectiveness of an NIF infusion in infants with congenital JET. Further, there have been only 5 case reports about CA during infancy for JET. An accumulation of a case series is needed to improve the outcome of CA during infancy. Here we describe 2 infants that underwent radiofrequency CA (RFCA) and clarify the successful ablation site and their complications.

Case 1
This patient was diagnosed with a fetal tachycardia, and a definitive diagnosis of JET was made just after birth. AMD infused at a dose of 5 mg/kg over 15 minutes induced cardiogenic shock. The JET did not improve with the administration of propranolol, aprindine, sotalol, bepridil, and landiolol. However, the JET rate was controlled by an intravenous NIF infusion at a rate of 0.8 mg/kg/h. Although we tried to replace NIF with an oral administration of AMD (20 mg/kg), the JET rate could not be controlled by AMD despite an adequate blood concentration of 784 ng/mL. The patient was subsequently referred to our institution for RFCA at the age of 5 months with a body weight of 5.8 kg, and the patient had received a continuous infusion of NIF (0.8 mg/kg/h). Figure 1 shows the response to the NIF during the RFCA. The JET rate was markedly controlled by the NIF administration. The QT interval and corrected QT interval using Freidericia formula (FQTc) markedly increased from 268 ms and 384 ms to 389 ms and 483 ms, respectively, as the JET rate decreased from 178 beats per minute (bpm) to 115 bpm with the NIF administration. The diagnosis of JET was confirmed based on the following electrophysiological study findings: (1) a similar QRS morphology was observed between the tachycardia and atrial captured beat; (2) junctional beats were preceded by His bundle electrograms (HBEs) of which the His-ventricular (HV) interval was similar to the HV interval of the junctional beat captured by sinus beats; and (3) ventriculoatrial dissociation was present during the tachycardia. A radiofrequency (RF) application was delivered...
with a temperature control below 55°C and power limit of 30 W with a 5F ablation catheter (Ablaze 5F, Japan Lifeline, Tokyo, Japan). A successful ablation was achieved after 2 sessions. The JET did not convert to sinus rhythm with an RF delivery to the distal HBE and slow pathway potential (SPP) recording sites. The successful ablation was achieved at a site proximal to the previous delivery site, where the HBE was recorded by the bipolar electrodes and a relatively large atrial wave was recorded (Figure 2). Although a complete right branch block occurred during the RFCA, the AV conduction was preserved by atrial pacing at a rate faster than the junctional tachycardia rate during the applications (Supplementary Figure S1). Transient AV block occurred during atrial pacing at 150 paces per minute, so the energy delivery was immediately terminated. There has been no recurrence of the JET for 4 years.

Case 2
The patient had a fetal tachycardia, and a definitive diagnosis of congenital JET was made after birth. This patient had a clinical course similar to that of case 1 and was resistant to various antiarrhythmic drugs (atenolol, flecainide, sotalol, bepridil, and landiolol). AMD at a dose of 5 mg/kg/d was also ineffective, and only an NIF infusion at 0.4 mg/kg/h successfully reduced the JET rate from 185 bpm to 93 bpm. The patient was referred to a different hospital for RFCA; however, the JET was not resolved, and complete atrioventricular block (CAVB) developed. The patient was subsequently referred to our hospital for RFCA at the age of 9 months with a body weight of 7.4 kg. Figure 3 shows 2:1 exit block during the JET after the NIF administration. The JET rate decreased from 220 bpm to 110 bpm. The QT interval and FQTc changed from 347 ms and 534 ms to 368 ms and 450 ms, respectively, as the heart rate decreased from 220 bpm to 110 bpm. In our hospital, an electrophysiological study confirmed the diagnosis of JET and CAVB. The JET did not improve with an RF application to the proximal and distal HBE recording (Figure 2) and SPP sites. The RF applications were delivered in the same manner as in case 1. A successful ablation was achieved at the midseptal region of the tricuspid annulus, which was lower and more proximal than the previous unsuccessful site. No HBE was recorded, and the atrial electrograms were larger than the ventricular electrograms at that site (Figure 2). An epicardial pacemaker implantation was performed for the CAVB after the RFCA. No further JET has occurred for 2 years.

Discussion
Efficacy of nifekalant

Mechanism of slowing a JET by an Ikr blocker
NIF is a pure class III antiarrhythmic drug, which mainly blocks the Ikr current.8 The recommended therapeutic dose ranges from 0.2 to 0.4 mg/kg/h.7 It has a dose-dependent Ikr channel-blocking effect in the ventricles, sinoatrial node, and atrioventricular node, without affecting the L-type calcium channel current, sodium current, or inward rectifier potassium current. The attenuation of the time-dependent repolarization and increase in the action potential duration resulting from Ikr inhibition may increase the cycle length of the nodal automaticity.10–12 Interestingly, case 1 presented with a gradual decrease in the JET rate without QT prolongation. This may have been caused by the Ikr-blocking effect on the abnormal foci by suppression of the automaticity. In contrast, case 2 presented with a 2:1 exit block without a reverse rate-dependent QT response. This conduction block could have occurred between the abnormal foci and proximal His bundle because of the absence of an HBE at the time of the block.

Potential differences in the efficacy between AMD and NIF
Why was NIF more effective than AMD in reducing the JET rate despite having a similar mechanism of blocking the Ikr current? AMD is lipid soluble and a multichannel drug that includes a potassium channel–blocker effect, whereas NIF is water soluble with a rapid onset of action and a pure Ikr blocker. Therefore, the drug concentration of an Ikr blockade...
can be more effectively increased with NIF than with AMD. Furthermore, the action potential duration, effective refractory period, and QT interval were significantly prolonged during the NIF administration compared with those for AMD.13

Adverse events
Neither case had any adverse event, such as torsade de points or hypotension, during the NIF administration. A high dose of AMD (10-mg load during the first hour plus a maintenance dose of 10 mg/kg/d) is frequently associated with adverse events (90%) such as hypotension, bradycardia, and vomiting,14 but a modest dose and titration of AMD can be safe. A dose of 5 mg/kg over 15 minutes might have been associated with hypotension in case 1. Because NIF has a positive inotropic effect,12 it was easily administered during the hemodynamic instability of the JET.

CA of JET in infancy
There have been only 5 cases previously reported that have required CA during a patient’s infancy.2–4,6,7 All 5 cases were successfully ablated, but the incidence of complications was high. Among those 5 cases, 1 permanent and 2 temporary occurrences of CAVB were reported.

Successful ablation site
The successful ablation sites were the para-Hisian area and midseptal region of the tricuspid annulus, as reported in previous studies.3,4,6 There are several ways to resolve JET, such as applying energy at the HBE recording site where the tachycardia rate can be decreased by the mechanical manipulation of the ablation catheter15 or by the application of energy at the earliest retrograde atrial activation site when ventriculoatrial conduction is present.16 In the first case, the JET converted to sinus rhythm by delivering RF energy at the HBE recording site, and there was no effect when RF applications were delivered at the distal HBE recording and SPP sites. In the second case, ablation at the midseptal region of the tricuspid annulus had no effect when delivered at the proximal HBE recording site.
Prevention of complications

It is beneficial to preserve the AV conduction by performing atrial pacing during the energy application or delivering the application from a low-dose energy. In our case, monitoring the AV conduction by atrial pacing contributed to preventing CAVB. Cryoablation would be a better choice for avoiding CAVB. However, RF ablation with 5F or 6F catheters was used in the previous reports, because a 7F cryoablation catheter is too big for small infants. We performed RFCA in the 2 infants because cryoablation was unavailable in Japan at that time. The success rates of cryoablation and RFCA are similar, but AV block is more frequent with RFCA than with cryoablation in older patients with JET. Although 4- and 6-mm-tip, 7F cryoablation catheters are currently available, they cannot be used below a certain body size. Cryoablation cannot be performed until an adequate body size is met. RF energy delivered with a 5F ablation catheter may be required for patients with body weights of less than approximately 5 kg.

Conclusions

To the best of our knowledge, this is the first report of the effectiveness of an NIF infusion to control the rate of congenital JET with 2 different mechanisms of action. Thus, in the future, a pure Ikr blocker may contribute to treating these arrhythmias. As a last resort, CA of JET in infancy is possible, however, it is associated with a very high risk of AV block. Cryoablation is preferred when the infant is large enough for a 7F cryoablation catheter to be used. Further studies are required to establish a better treatment for congenital JET.

Appendix

Supplementary data

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.hrcr.2017.03.005.

References

1. Walsh EP, Saul JP, Triedman JK, eds. Cardiac Arrhythmias in Children and Young Adults with Congenital Heart Disease. Philadelphia, PA: Lippincott Williams and Wilkins; 2001. p. 5–22.
2. Fishberger SR, Rossi AF, Messina JJ, Saul JP. Successful radiofrequency catheter ablation of congenital junctional ectopic tachycardia with preservation of atrioventricular conduction in a 9-month-old infant. Pacing Clin Electrophysiol 1998;21:2132–2135.
3. Rychik J, Marchlinski FE, Sweeten TL, Berul CI, Bhat AM, Collins-Burke C, Vetter VL. Transcatheter radiofrequency ablation for congenital junctional ectopic tachycardia in infancy. Pediatr Cardiol 1997; 18:447–450.
4. Van Hare GF, Velvis H, Langberg JJ. Successful transcatheter ablation of congenital junctional ectopic tachycardia in a ten-month-old infant using radiofrequency energy. Pacing Clin Electrophysiol 1990;13:730–735.
5. Hachiya H, Hiroko K, Takahashi A, Nagata Y, Suzuki K, Mieda S, Sasaki T, Kawabata M, Isobe M, Isaka Y. Clinical implications of reconnection between the left atrium and isolated pulmonary veins provoked by adenosine triphosphate after extensive encircling pulmonary vein isolation. J Cardiovasc Electrophysiol 2007;18:392–398.
6. Bae EJ, Kang SJ, Noh CI, Choi JY, Yun YS. A case of congenital junctional ectopic tachycardia: diagnosis and successful radiofrequency catheter ablation in infancy. Pacing Clin Electrophysiol 2005;28:254–257.
7. Berul CI, Hill SL, Wang PJ, Marx GR, Fulton DR, Estes NA 3rd. Neonatal radiofrequency catheter ablation of junctional tachycardias. J Interv Card Electrophysiol 1998;2:91–100.
8. Nakayama T, Totsue N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993;109:157–163.
9. Oyabe A, Sano H. Pharmacological and clinical profile of nifekalant (shinbit in jection), a class III antiarrhythmic drug [in Japanese]. Nippon Yakurigaku Zasshi 2002;119:103–109.
10. Verheijck EE, van Ginneken AC, Bourier J, Bouman LN. Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. Circ Res 1995;76:607–615.
11. Clark RB, Mangoni ME, Lueter A, Couette B, Nargeot J, Giles WR. A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells. Am J Physiol Heart Circ Physiol 2004; 286:H1757–H1766.
12. Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol 1996;27:159–166.
13. Sonoko Ashino IW, Kobune Masayoshi, Hirayama Atsushi. Effects of antiarhythmic class III drugs on chronic atrial fibrillation. Progress in Medicine 2008;28:568–572 (in Japanese).
14. Saul JP, Scott WA, Brown S, et al. Intravenous Amiodarone Pediatric Investigators. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470–3477.
15. Young ML, Mehta MB, Martinez RM, Wolff GS, Gelband H. Combined alpha-adrenergic blockade and radiofrequency ablation to treat junctional ectopic tachycardia successfully without atrioventricular block. Am J Cardiol 1993; 71:883–885.
16. Handan M, Van Hare GF, Fisher W, Gonzalez R, Dorostkar P, Lee R, Lesh M, Suxon L, Kalman J, Schumman M. Selective catheter ablation of the tachycardia focus in patients with nonreentrant junctional tachycardia. Am J Cardiol 1996; 78:1292–1297.
17. Fukushima H, Nakamura Y, Ohmishi T. Atrial pacing during radiofrequency ablation of junctional ectopic tachycardia a useful technique for avoiding atrioventricular block. Jpn Circ J 2001;65:242–244.
18. Wu MH, Wang JK, Lin HL, Lai LP, Lai HC, Young ML, Hsieh FJ. Supraventricular tachycardia in patients with right atrial isomerism. J Am Coll Cardiol 1998; 32:773–779.
19. Collins KK, Van Hare GF, Kertesz NJ, et al. Pediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies. J Am Coll Cardiol 2009;53:690–697.